{{header
 | author     = 
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2013
 | month      = 07
 | day        = 10
 | notes      = ''{{USBill|113|S.|1277}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 1
 | title      = Combating Prescription Drug Abuse Act ( S. 1277; 113th Congress)
 | bill       = 1277
 | billtype   = s
 | purpose    = To establish a commission for the purpose of coordinating efforts to reduce prescription drug abuse, and for other purposes.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|1st Session}}

 
{{Center|S. 1277}}

 
{{Center|IN THE SENATE OF THE UNITED STATES}}

  
{{Center|July 10, 2013}}

 
{{Center| 
[[w:|Mrs. Boxer]] introduced the following bill; which was read twice and referred to the [[w:United States Senate Committee on Health, Education, Labor, and Pensions|Committee on Health, Education, Labor, and Pensions]]  }}

  
{{Center|A BILL}}

 To establish a commission for the purpose of coordinating efforts to reduce prescription drug abuse, and for other purposes.   

=Section 1. Short title=

This Act may be cited as the“ Combating Prescription Drug Abuse Act ”. 

=Sec. 2. Commission=



==(a) Establishment– ==

There is established the [[w:|Combating Prescription Drug Abuse Commission]] (referred to in this Act as the Commission ).

==(b) Membership– ==



===(1) Appointment– ===

The [[w:|Commission]] shall be composed of 30 members. Such members shall be appointed by the [[w:Government Accountability Office|Comptroller General of the United States]] , in consultation with the [[w:Department of Health and Human Services|Secretary of Health and Human Services]] and the [[w:United States Department of Justice|Attorney General]] .

===(2) Composition– ===

The members appointed under paragraph (1) shall include an equitable balance of individuals representing health care groups and law enforcement groups, including—
:(A) a representative of the [[w:Drug Enforcement Administration|Drug Enforcement Administration]] ;
:(B) a representative of the [[w:Food and Drug Administration|Food and Drug Administration]] ;
:(C) a representative of the [[w:Office of National Drug Control Policy|Office of National Drug Control Policy]] ;
:(D) representatives of patient, advocacy, and community-based groups;
:(E) representatives of pharmacy, prescribers, hospitals, wholesalers, dispensers, manufacturers, and other health care groups;
:(F) public policy experts;
:(G) representatives of State attorneys general; and
:(H) representatives of law enforcement officials, including local law enforcement officials.

===(3) Date of appointment– ===

The appointments of the members of the [[w:|Commission]] shall be made not later than 180 days after the date of enactment of this Act.

===(4) Co-Chairs– ===

The representative of the [[w:Drug Enforcement Administration|Drug Enforcement Administration]] and the representative of the [[w:Food and Drug Administration|Food and Drug Administration]] shall serve as Co-Chairs of the [[w:|Commission]] .

===(5) Period of appointment; vacancies– ===

Members shall be appointed for the life of the [[w:|Commission]] . Any vacancy in the [[w:|Commission]] shall not affect its powers, but shall be filled in the same manner as the original appointment.

==(c) Meetings– ==

The [[w:|Commission]] shall meet at the call of the Co-Chairs. The [[w:|Commission]] shall meet for at least 2 public meetings, at which the [[w:|Commission]] shall provide opportunity for public input, comment, and suggestion.

==(d) Duties of the commission– ==



===(1) In general– ===

The [[w:|Commission]] shall—
:(A) review and report to [[w:United States Congress|Congress]] on Federal initiatives with respect to efforts to prevent and reduce prescription drug abuse;
:(B) identify gaps and opportunities with respect to ensuring the safe use of prescription drugs with the potential for diversion and abuse; and
:(C) make recommendations on specific ways to reduce diversion and abuse of prescription drugs.

===(2) Report– ===



====(A) In general– ====

Not later than 1 year after the date of enactment of this Act, the [[w:|Commission]] shall issue a report to [[w:United States Congress|Congress]] that describes the efforts of the [[w:|Commission]] to prevent or reduce drug diversion and abuse to ensure that patients continue to have access to medications.

====(B) Recommendations– ====

The report described in subparagraph (A) shall include specific recommendations for the [[w:Drug Enforcement Administration|Drug Enforcement Administration]] , the [[w:Food and Drug Administration|Food and Drug Administration]] , and other Federal and State agencies, as appropriate, and shall include the following topics:
:(i) Systems for prescription drug monitoring, which shall include proposals to increase the use and sustainability of prescription drug monitoring programs.
:(ii) Illegal Internet prescription drug sites and pill mills that distribute prescription drugs and fill prescriptions inappropriately.
:(iii) Facilitating proper disposal of prescription drugs, including public outreach and education efforts with respect to such proper disposal.
:(iv) Identifying active areas of prescription drug abuse.
:(v) Improving collaboration among Federal agencies, especially the [[w:Drug Enforcement Administration|Drug Enforcement Administration]] and the [[w:Food and Drug Administration|Food and Drug Administration]] .
:(vi) Improving collaboration between Federal agencies and relevant stakeholders, including the groups represented on the [[w:|Commission]] .
:(vii) The resource needs for law enforcement.
:(viii) Proposals to improve the education of providers, patients, parents, and youth.
:(ix) Development of abuse-resistant products.
:(x) Recommendations for reducing robberies, burglaries, and cargo theft.

==(e) Powers of the Commission– ==



===(1) Hearings– ===

The [[w:|Commission]] may hold such hearings, sit and act at such times and places, take such testimony, and receive such evidence as the [[w:|Commission]] considers advisable to carry out this section.

===(2) Information from Federal agencies– ===

The [[w:|Commission]] may secure directly from any Federal department or agency such information as the [[w:|Commission]] considers necessary to carry out this section. Upon the request of the Co-Chairs of the [[w:|Commission]] , the head of such department or agency shall furnish such information to the [[w:|Commission]] in a timely manner.

==(f) Confidentiality– ==

Information obtained by the [[w:|Commission]] from any Federal agency shall be exempt from disclosure under[http://www.law.cornell.edu/uscode/text/5/552  section 552of title 5, United States Code]. For purposes of the preceding sentence, this subsection shall be considered a statute described in[http://www.law.cornell.edu/uscode/text/5/552 subsection (b)(3)(B) of such section 552].

==(g) Termination of the commission– ==

The [[w:|Commission]] shall terminate 2 years after the date on which the members are appointed under subsection (b) .

==(h) Authorization of appropriations– ==



===(1) In general– ===

 There is authorized to be appropriated $3,000,000 for fiscal years 2014 through 2016to the [[w:|Commission]]  to carry out this section  . 

===(2) Limitation on use of funds– ===

No funds appropriated under paragraph (1) may be used to carry out the recommendations of the [[w:|Commission]] .  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
